Library

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis / R.N. de Nijs in The New England journal of medicine, 355(2006)7 ([08/17/2006])  

[article] Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis [printed text] / R.N. de Nijs, Author ; J.W. Jacobs, Author ; W.F. Lems, Author ; R.F. Laan, Author ; A. Algra, Author ; A.M. Huisman, Author ; E. Buskens, Author ; Chris De Laet , Author . - 2006 . - 675-84. Languages : English (eng) in The New England journal of medicine > 355(2006)7 [08/17/2006] . - 675-84 Descriptors: Classification W 1 Serials. Periodicals Indexation Aged ; Bone Density ; Bone Diseases, Metabolic ; Double-Blind Method ; drug therapy ; Female ; Humans ; Journal Article ; Male ; Middle Aged ; Osteoporosis ; Peer Review ; Spine ; United States Abstract: BACKGROUND: Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS: We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration among patients with a rheumatic disease who were starting glucocorticoids at a daily dose that was equivalent to at least 7.5 mg of prednisone. A total of 201 patients were assigned to receive either alendronate (10 mg) and a placebo capsule of alfacalcidol daily or alfacalcidol (1 microg) and a placebo tablet of alendronate daily. The primary outcome was the change in bone mineral density of the lumbar spine in 18 months; the secondary outcome was the incidence of morphometric vertebral deformities. RESULTS: A total of 100 patients received alendronate, and 101 received alfacalcidol; 163 patients completed the study. The bone mineral density of the lumbar spine increased by 2.1 percent in the alendronate group (95 percent confidence interval, 1.1 to 3.1 percent) and decreased by 1.9 percent in the alfacalcidol group (95 percent confidence interval, -3.1 to -0.7 percent). At 18 months, the mean difference of change in bone mineral density between the two groups was 4.0 percent (95 percent confidence interval, 2.4 to 5.5 percent). Three patients in the alendronate group had a new vertebral deformity, as compared with eight patients in the alfacalcidol group (of whom three had symptomatic vertebral fractures) (hazard ratio, 0.4; 95 percent confidence interval, 0.1 to 1.4). CONCLUSIONS: During this 18-month trial in patients with rheumatic diseases, alendronate was more effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol. (ClinicalTrials.gov number, NCT00138983 [ClinicalTrials.gov].). Link for e-copy: http://www.nejm.org/doi/pdf/10.1056/NEJMoa053569 Format of e-copy: PDF [Open Access] (230 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2159 [article]

Alendroninezuur effectiever dan alfacalcidol voor preventie van osteoporose bij patiënten met een reumatische ziekte die starten met glucocorticoïdtherapie / R.N. de Nijs in Nederlands tijdschrift voor geneeskunde, 351(2007)21 ([05/26/2007])  

[article] Alendroninezuur effectiever dan alfacalcidol voor preventie van osteoporose bij patiënten met een reumatische ziekte die starten met glucocorticoïdtherapie = Alendronate more effective than alfacalcidol in the prevention of osteoporosis in patients with rheumatic disease who are starting glucocorticoid therapy [printed text] / R.N. de Nijs, Author ; J.W. Jacobs, Author ; W.F. Lems, Author ; R.F. Laan, Author ; E. Buskens, Author ; A. Algra, Author ; A.M. Huisman, Author ; Chris De Laet , Author . - 2007 . - 1178-85. Languages : Dutch (nla) in Nederlands tijdschrift voor geneeskunde > 351(2007)21 [05/26/2007] . - 1178-85 Descriptors: Classification W 1 Serials. Periodicals Indexation Disease ; Journal Article ; Netherlands ; Osteoporosis ; Peer Review ; Rheumatic Diseases ; Therapy Abstract: OBJECTIVE: To compare the effects of alendronate and alfacalcidol in the prevention ofglucocorticoid-related osteoporosis in patients with a rheumatic disease. DESIGN: Randomised, double-blind, double-placebo clinical trial (www. clinicaltrials.gov; number: NCT00138983). METHODS: A total of 201 patients with rheumatic disease who were starting glucocorticoid treatment at a daily dose that was equivalent to at least 7.5 mg of prednisone were randomised to alendronate (10 mg) and a placebo capsule ofalfacalcidol daily (n = 100) or alfacalcidol (1 microg) and a placebo tablet ofalendronate daily (n = 101) for 18 months. Primary outcome was change in lumbar spine bone mineral density at 18 months. The main secondary outcome was the incidence of morphometrically confirmed vertebral deformities. RESULTS: Overall, 163 patients completed the study. The bone mineral density of the lumbar spine increased by 2.1% (95% CI: 1.1-3.1) in the alendronate group and decreased by 1.9% (95% CI: -3.I--0.7) in the alfacalcidol group. At 18 months the mean difference in change in bone mineral density between the two groups was 4.0% (95% CI: 2.4-5-5). Three patients in the alendronate group had a new vertebral deformity, compared with 8 patients in the alfacalcidol group, including 5 symptomatic vertebral fractures in 3 patients; the hazard ratio was 0.4 (95% CI: 0.1-1.4). CONCLUSION: Alendronate was more effective than alfacalcidol in preventing glucocorticoid-induced bone loss during this 18-month trial in patients with rheumatic diseases who were starting glucocorticoid treatment. Link for e-copy: http://www.ntvg.nl/publicatie/alendroninezuur-effectiever-dan-alfacalcidol-voor- [...] Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2152 [article]

De doelmatige behandelingen voor de preventie van breuken ten gevolge van osteoporose / Comité voor de evaluatie van de medische praktijk inzake geneesmiddelen = Comité d'évaluation des pratiques médicales en matière de médicaments / Bruxelles [Belgium] : Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) = Institut National Maladie Invalidité (INAMI) (2005)  

De doelmatige behandelingen voor de preventie van breuken ten gevolge van osteoporose [printed text] / Comité voor de evaluatie van de medische praktijk inzake geneesmiddelen = Comité d'évaluation des pratiques médicales en matière de médicaments, Author . - Bruxelles [Belgium] : Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) = Institut National Maladie Invalidité (INAMI), 2005 . - 61 p. : ill.. - (Juryrapport; Mei) . € 0 Consensusvergadering 26 mei 2005 - Juryrapport Volledige (lange) tekst Languages : Dutch (dut) Descriptors: Indexation Belgium ; Consensus Development Conferences ; Female ; Fractures, Bone ; Health Care ; Osteoporosis ; Primary Prevention ; Therapy Classification WE 250 Osteoporosis Abstract: De doelstelling van de conferentie was de doelmatige behandeling na te gaan voor de preventie van breuken ten gevolge van osteoporose bij postmenopauzale vrouwen at risk voor osteoporotische breuken met uitsluiting van vroegtijdige menopauze, mannelijke osteoporose en corticoïdgeïnduceerde osteoporose. Link for e-copy: http://www.inami.fgov.be/drug/nl/statistics-scientific-information/consensus/200 [...] Format of e-copy: PDF [Open Access] (525 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2045

Geneesmiddelen ter preventie van osteoporosische fracturen / Dominique Roberfroid / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)  

Geneesmiddelen ter preventie van osteoporosische fracturen [printed text] / Dominique Roberfroid , Author ; Cécile Camberlin , Author ; Cécile Dubois , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - X, 106 p. : ill. ; A4. - (KCE Reports A. Good Clinical Practice (GCP); 159A) . ISSN : D/2011/10.273/32 : € 0,00 Studie nr 2009-1 (2nd print; 1st print: 4 juillet 2011) Languages : English (eng) Dutch (nla) Descriptors: Indexation 2009-01 ; Diphosphonate ; Fractures, Bone ; Mass Screening ; Osteoporosis ; Primary Prevention ; R159 Classification WE 250 Osteoporosis Abstract: Medicatie ter preventie van broosheidsfracturen wordt het beste voorbehouden voor patiënten met een hoog risico op een breuk, zoals degenen die al eerder zulke breuk hadden, zegt het Federaal Kenniscentrum voor de Gezondheidszorg (KCE). Toch neemt maar 1 op 5 van de patiënten die een broosheidsfractuur hadden deze geneesmiddelen, en de helft van de gebruikers stopt binnen het jaar met de behandeling. Anderzijds gebruiken mensen met een matig risico op fracturen deze geneesmiddelen beter niet, want het medische voordeel weegt niet op tegen de mogelijke neveneffecten. Contents note: 1 INTRODUCTION 2 -- 2 BELGIAN SITUATION ANALYSIS 4 -- 2.1 METHODS 4 -- 2.1.1 Data sources 4 -- 2.1.2 Epidemiology of fragility fractures 4 -- 2.1.3 Osteoporosis drugs consumption 5 -- 2.2 RESULTS 7 -- 2.2.1 Epidemiology of hip, humerus, vertebral and wrist fractures 7 -- 2.2.2 Utilization of osteoporosis drugs 10 -- 2.2.3 Reimbursement rules 22 -- 2.3 DISCUSSION 25 -- 3 SCREENING FOR PATIENTS AT HIGH RISK OF FRACTURES 27 -- 3.1 METHODS 27 -- 3.2 RESULTS 27 -- 3.2.1 Measuring BMD 28 -- 3.2.2 Prediction models 30 -- 3.2.3 Biochemical markers 33 -- 3.2.4 Effectiveness of screening for osteoporosis 33 -- 3.3 DISCUSSION 36 -- 4 EFFICACY OF PHARMACOLOGICAL TREATMENT 37 -- 4.1 METHODS 37 -- 4.2 RESULTS 40 -- 4.2.1 Biphosphonates 40 -- 4.2.2 Strontium ranelate 45 -- 4.2.3 Calcitonin 47 -- 4.2.4 Selective Estrogen Receptor Modulators (SERM): Raloxifene 47 -- 4.2.5 Denosumab 48 -- 4.3 DISCUSSION 48 -- 4.3.1 Influence of fracture site 48 -- 4.3.2 Influence of baseline risk 49 -- 4.3.3 Influence of treatment duration 50 -- 4.3.4 Influence of treatment type 51 -- 4.3.5 Safety issues 52 -- 5 GUIDELINES FOR OSTEOPOROSIS MANAGEMENT 54 -- 5.1 METHODS 54 -- 5.2 RESULTS 54 -- 5.3 DISCUSSION 54 -- 6 RECOMMENDATIONS 61 -- 6.1 RECOMMENDATIONS FOR CLINICIANS 61 -- 6.2 RECOMMENDATIONS FOR POLICY-MAKERS 62 -- 6.3 RECOMMENDATIONS FOR RESEARCHERS 62 -- 7 APPENDIXES 63 -- 7.1 APPENDIXES ON BELGIAN SITUATION ANALYSIS 63 -- 7.2 APPENDIXES ON SCREENING FOR OSTEOPOROSIS 93 -- 7.3 APPENDIXES ON TREATMENT EFFICACY 97 -- 8 REFERENCES 89 Link for e-copy: https://kce.fgov.be/sites/default/files/page_documents/kce_159a_osteoporosis.pdf Format of e-copy: PDF (1,45 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2623

Copies

Barcode	Call number	Media type	Location	Section	Status
No copy

Readers who borrowed this document also borrowed:

Social sciences	Library of Congress
Logiciels libres en gestion de l'information	Remize, Michel
Science	Library of Congress
Gebruik van point-of care systemen bij patiënten met orale anticoagulatie	Gailly, Jeannine
Manuel pratique de bibliothéconomie	Vanzieleghem, Eric
Licensing digital content	Harris, Lesley Ellen
Pratique de MySQL et PHP	Rigaux, Philippe
Les publications électroniques	Remize, Michel
Rapport coût-utilité de la vaccination contre la varicelle chez les enfants, et de la vaccination contre le zona chez les adultes en Belgique.	Bilcke, J
Office 2007	Shoup, Kate
Technology	Library of Congress

Osteoporosis international / John A. Kanis, / Berlin - Heidelberg [Germany] : Springer-Verlag (1990)  

[serial]  See available issues Search in serial Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. [printed text] / John A. Kanis,, Publishing director ; Robert Lindsay, Publishing director . - Berlin - Heidelberg [Germany] : Springer-Verlag, 1990. ISSN : 0937-941X IF : http://www.springer.com/medicine/orthopedics/journal/198 SJR : http://www.scimagojr.com/journalsearch.php?q=16453&tip=sid&clean=0 Indexed : MEDLINE (1990-....) Reader accessibility : http://jinfo.lub.lu.se/jinfo?func=fullRecord&jId=3120&issn=0937941X Languages : English (eng) Descriptors: Classification W 1 Serials. Periodicals Indexation Germany ; Osteoporosis ; Peer Review ; Periodicals Abstract: An international multi-disciplinary journal which is a joint initiative between the International Osteoporosis Foundation and the National Osteoporosis Foundation of the USA, Osteoporosis International provides a forum for the communication and exchange of current ideas concerning the diagnosis, prevention, treatment and management of osteoporosis and other metabolic bone diseases. It publishes: original papers - reporting progress and results in all areas of osteoporosis and its related fields; review articles - reflecting the present state of knowledge in special areas of summarizing limited themes in which discussion has led to clearly defined conclusions; educational articles - giving information on the progress of a topic of particular interest; case reports - of uncommon or interesting presentations of the condition. Link for e-copy: http://vdic.idm.oclc.org/login?url=https://www.springer.com/journal/198 Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2148 [serial]  See available issues Search in serial

Osteoporosis / Robert Marcus / Amsterdam : Elsevier/Academic Press (2008)

Permalink

Osteoporosis / Robert Marcus / Amsterdam : Elsevier/Academic Press (2008)

Permalink

Pharmacological prevention of fragility fractures in Belgium / Dominique Roberfroid / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)  

Permalink

Prévention médicamenteuse des fractures ostéoporotiques / Dominique Roberfroid / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)  

Permalink

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women / John A. Kanis, in Osteoporosis international, 19(2008)4 ([04/01/2008])  

Permalink

Les traitements efficients pour la prévention des fractures liées à l’ostéoporose / Comité voor de evaluatie van de medische praktijk inzake geneesmiddelen = Comité d'évaluation des pratiques médicales en matière de médicaments / Bruxelles [Belgium] : Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV) = Institut National Maladie Invalidité (INAMI) (2005)  

Permalink